Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

References

• Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28:468–476.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242–251.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Roberto-Perez-Alvarez R-P, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9:188–193.
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56–64.
   PubMed Web of Science ®Google Scholar
• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9–14.
   PubMed Web of Science ®Google Scholar
• Lonberg N, Korman AJ. Masterful antibodies: checkpoint blockade. Cancer Immunol Res. 2017;5:275–281.
   PubMed Web of Science ®Google Scholar
• Babouri A, Roblin X, Filippi J, et al. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study. J Crohns Colitis. 2014;8:161–165.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66:732–739.
   PubMed Web of Science ®Google Scholar
• Charles PJ, Smeenk RJ, de Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383–2390.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Loftus EVJ, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1308–1319.
   PubMed Web of Science ®Google Scholar
• Comby E, Tanaff P, Mariotte D, et al. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol. 2006;33:24–30.
   PubMed Web of Science ®Google Scholar
• Exarchou SA, Voulgari PV, Markatseli TE, et al. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol. 2009;38:328–331.
   PubMed Web of Science ®Google Scholar
• Flendrie M, Vissers WHPM, Creemers MCW, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666–R676.
   PubMed Web of Science ®Google Scholar
• Freling E, Baumann C, Cuny J-F, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110:1186–1196.
   PubMed Web of Science ®Google Scholar
• Gonnet-Gracia C, Barnetche T, Richez C, et al. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol. 2008;26:401–407.
   PubMed Web of Science ®Google Scholar
• Jani M, Dixon WG, Kersley-Fleet L, et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open. 2017;3:e000314.
   PubMedGoogle Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1-e15.
   PubMed Web of Science ®Google Scholar
• Nancey S, Blanvillain E, Parmentier B, et al. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn’s disease. Inflamm Bowel Dis. 2005;11:986–991.
   PubMed Web of Science ®Google Scholar
• Poulalhon N, Begon E, Lebbe C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156:329–336.
   PubMed Web of Science ®Google Scholar
• Takase K, Horton SC, Ganesha A, et al. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann Rheum Dis. 2014;73:1695–1699.
   PubMed Web of Science ®Google Scholar
• Verma HD, Scherl EJ, Jacob VE, et al. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab. J Dig Dis. 2011;12:379–383.
   PubMed Web of Science ®Google Scholar
• Guarneri C, Lentini M, Polimeni G, et al. Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus. Br J Clin Pharmacol. 2016;81:792–794.
   PubMed Web of Science ®Google Scholar
• Richez C, Dumoulin C, Schaeverbeke T. Infliximab induced chilblain lupus in a patient with rheumatoid arthritis. J Rheumatol. 2005;32:760–761.
   PubMed Web of Science ®Google Scholar
• Sohl S, Renner R, Winter U, et al. [Drug-induced lupus erythematosus tumidus during treatment with adalimumab]. Hautarzt. 2009;60:826–829. German.
   PubMed Web of Science ®Google Scholar
• Caramaschi P, Ravagnani V, Bambara LM, et al. Is the family history positive for SLE a predisposing factor for anti-TNFalpha blockers induced lupus? A case report. Joint Bone Spine. 2010;77:484–485.
   Web of Science ®Google Scholar
• Beigel F, Schnitzler F, Paul Laubender R, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:91–98.
   PubMed Web of Science ®Google Scholar
• Pontikaki I, Shahi E, Frasin LA, et al. Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2012;42:131–134.
   PubMed Web of Science ®Google Scholar
• Sokumbi O, Wetter DA, Makol A, et al. Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin Proc. 2012;87:739–745.
   PubMed Web of Science ®Google Scholar
• Tarkiainen M, Tynjala P, Vahasalo P, et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford). 2015;54:1170–1176.
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Bandinelli F, et al. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol. 2008;26:S23–S29.
   PubMed Web of Science ®Google Scholar
• Belkhir R, Le Burel S, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017. doi: 10.1136/annrheumdis-2017211216.
   PubMed Web of Science ®Google Scholar
• Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34–44.
   PubMed Web of Science ®Google Scholar
• Kip KE, Swoger JM, Grandinetti LM, et al. Tumor necrosis factor alpha antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Inflamm Bowel Dis. 2013;19:1164–1172.
   PubMed Web of Science ®Google Scholar
• Afzali A, Wheat CL, Hu JK, et al. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8:480–488.
   PubMed Web of Science ®Google Scholar
• Aslanidis S, Pyrpasopoulou A, Douma S, et al. Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol. 2008;27:377–380.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Grittner U, Steingraber A, et al. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:2512–2520.
   PubMed Web of Science ®Google Scholar
• Cleynen I, van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164:10–22.
   PubMed Web of Science ®Google Scholar
• Dalkilic E, Bulbul Baskan E, Alkis N, et al. Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Mod Rheumatol. 2012;22:738–742.
   PubMed Web of Science ®Google Scholar
• Fouache D, Goeb V, Massy-Guillemant N, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford). 2009;48:761–764.
   PubMed Web of Science ®Google Scholar
• George LA, Gadani A, Cross RK, et al. Psoriasiform skin lesions are caused by anti-TNF agents used for the treatment of inflammatory bowel disease. Dig Dis Sci. 2015;60:3424–3430.
   PubMed Web of Science ®Google Scholar
• Guerra I, Algaba A, Perez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6:518–523.
   PubMed Web of Science ®Google Scholar
• Guerra I, Perez-Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22:894–901.
   PubMed Web of Science ®Google Scholar
• Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209–215.
   PubMed Web of Science ®Google Scholar
• Hellstrom AE, Farkkila M, Kolho K-L. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51:563–571.
   PubMed Web of Science ®Google Scholar
• Hwang SJE, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74:455–61.e1.
   PubMed Web of Science ®Google Scholar
• Lee -H-H, Song I-H, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486–491.
   PubMed Web of Science ®Google Scholar
• Protic M, Schoepfer A, Yawalkar N, et al. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels. Scand J Gastroenterol. 2016;51:1482–1488.
   PubMed Web of Science ®Google Scholar
• Thomas L, Canoui-Poitrine F, Gottenberg J-E, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol. 2012;39:893–898.
   PubMed Web of Science ®Google Scholar
• Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567–577.
   PubMed Web of Science ®Google Scholar
• Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–209.
   PubMed Web of Science ®Google Scholar
• Ten Tusscher MPM, Jacobs PJC, Busch MJWM, et al. Bilateral anterior toxic optic neuropathy and the use of infliximab. Bmj. 2003;326:579.
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Zikou AK, Voulgari PV, et al. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16:R125.
   PubMed Web of Science ®Google Scholar
• Corrie PG, Marshall A, Dunn JA, et al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 2014;15:620–630.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Chen L, Fraunfelder FW, et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol. 2013;155:183–189.e1.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Sibilia J, Mariette X, et al. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–266.
   PubMed Web of Science ®Google Scholar
• Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.
   PubMed Web of Science ®Google Scholar
• Deepak P, Stobaugh DJ, Sherid M, et al. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther. 2013;38:388–396.
   PubMed Web of Science ®Google Scholar
• Tsouni P, Bill O, Truffert A, et al. Anti-TNF alpha medications and neuropathy. J Peripher Nerv Syst. 2015;20:397–402.
   PubMed Web of Science ®Google Scholar
• O’Toole A, Lucci M, Korzenik J. Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA. Dig Dis Sci. 2016;61:1772–1774.
   PubMed Web of Science ®Google Scholar
• Barthel D, Ganser G, Kuester R-M, et al. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42:2160–2165.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007;57:639–647.
   PubMed Web of Science ®Google Scholar
• Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145–1152.
   PubMed Web of Science ®Google Scholar
• Gold R, Radue E-W, Giovannoni G, et al. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016;16:117.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234–240.
   PubMed Web of Science ®Google Scholar
• Klotsche J, Niewerth M, Haas J-P, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75:855–861.
   PubMed Web of Science ®Google Scholar
• van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011;38:1441–1446.
   PubMed Web of Science ®Google Scholar
• Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591–5598.
   PubMed Web of Science ®Google Scholar
• Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77:573–579.
   PubMed Web of Science ®Google Scholar
• Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–1101.
   PubMed Web of Science ®Google Scholar
• Flaig T, Douros A, Bronder E, et al. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2016;41:718–721.
   PubMed Web of Science ®Google Scholar
• Alabed YZ, Aghayev A, Sakellis C, et al. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin Nucl Med. 2015;40:e528–e529.
   PubMed Web of Science ®Google Scholar
• Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report. Lung Cancer. 2016;99:148–150.
   PubMed Web of Science ®Google Scholar
• Abdulkader R, Dharmapalaiah C, Rose G, et al. Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol. 2014;41:858–861.
   PubMed Web of Science ®Google Scholar
• Aguiar-Bujanda D, Blanco-Sanchez MJ, Hernanten Tusscherz-Sosa M, et al. Late-onset neutropenia after rituximab-containing therapy for non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:761–765.
   PubMed Web of Science ®Google Scholar
• Albattal BM. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor. Ann Saudi Med. 2016;36:190–196.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15:6446–6453.
   PubMed Web of Science ®Google Scholar
• Arai Y, Yamashita K, Mizugishi K, et al. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. Hematology. 2015;20:196–202.
   PubMed Web of Science ®Google Scholar
• Aslanidis S, Pyrpasopoulou A, Triantafyllou A, et al. Tumor necrosis factor antagonist-associated neutropenia: comment on the article by Hastings et al. Arthritis Care Res (Hoboken). 2010;62:1813–1815.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840–847.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma. 2006;47:1013–1017.
   PubMed Web of Science ®Google Scholar
• Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121:913–918.
   PubMed Web of Science ®Google Scholar
• Ciancio G, Gaynor JJ, Sageshima J, et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. Transplantation. 2011;92:1348–1357.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395.
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75:1506–1510.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13:879–886.
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Santegoets SJAM, Reyners AKL, et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol Off J Eur Soc Med Oncol. 2015;26:2141–2149.
   PubMed Web of Science ®Google Scholar
• Dy GK, Molina JR, Qi Y, et al. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol. 2014;9:1146–1153.
   PubMed Web of Science ®Google Scholar
• Espinoza F, Le Blay P, Combe B. Biologic disease-modifying antirheumatic drug (bDMARD)-induced neutropenia: a registry from a retrospective cohort of patients with rheumatic diseases treated with 3 classes of intravenous bDMARD. J Rheumatol. 2017;44:844–849.
   PubMed Web of Science ®Google Scholar
• Fujinaga S, Ozawa K, Sakuraya K, et al. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol. 2016;85:340–345.
   PubMed Web of Science ®Google Scholar
• Fukuno K, Tsurumi H, Ando N, et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin’s lymphoma. Int J Hematol. 2006;84:242–247.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412–1419.
   PubMed Web of Science ®Google Scholar
• Godinho F, Godfrin B, El Mahou S, et al. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:328–330.
   PubMed Web of Science ®Google Scholar
• Guglieri-Lopez B, Perez-Pitarch A, Porta Oltra B, et al. Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting. Anticancer Drugs. 2016;27:679–684.
   PubMed Web of Science ®Google Scholar
• Hirayama Y, Kohda K, Konuma Y, et al. Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab. Intern Med. 2009;48:57–60.
   PubMed Web of Science ®Google Scholar
• Hong YS, Lee SS, Kim K, et al. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. Am J Clin Oncol. 2014;37:19–23.
   PubMed Web of Science ®Google Scholar
• Horinouchi H, Yamamoto N, Fujiwara Y, et al. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs. 2015;33:881–889.
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542–552.
   PubMed Web of Science ®Google Scholar
• Ishida H, Inui M, Furusawa M, et al. Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation–single-center study. Transpl Immunol. 2013;28:93–99.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96.
   PubMed Web of Science ®Google Scholar
• Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156–2168.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32:3096–3102.
   PubMed Web of Science ®Google Scholar
• Kamei K, Takahashi M, Fuyama M, et al. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant. 2015;30:91–96.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Lee -S-S, Byun BH, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2013;71:945–953.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033–8040.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Wallace T, Olech E, et al. Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study. Rheumatol Ther. 2016;3:291–304.
   PubMed Web of Science ®Google Scholar
• Knight A, Sundström Y, Börjesson O, et al. Late-onset neutropenia after rituximab in ANCA-associated vasculitis. Scand J Rheumatol. 2016;45:404–407.
   PubMed Web of Science ®Google Scholar
• Lai GGY, Lim S-T, Tao M, et al. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol. 2009;84:414–417.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497–1508.
   PubMed Web of Science ®Google Scholar
• Le Stradic C, Galeotti C, Kone-Paut I. [Tocilizumab: experience in a French rheumatological pediatric center]. Arch Pediatr. 2014;21:1299–1304. French.
   PubMed Web of Science ®Google Scholar
• Lehman TJ, Singh C, Ramanathan A, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J. 2014;12:3.
   PubMed Web of Science ®Google Scholar
• Leon L, Vázquez S, Gracia JM, et al. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naive patients. Expert Opin Pharmacother. 2012;13:1389–1396.
   PubMed Web of Science ®Google Scholar
• Levälampi T, Korpela M, Vuolteenaho K, et al. Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int. 2008;28:261–269.
   PubMed Web of Science ®Google Scholar
• Li S-C, Chen Y-C, Evens AM, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphism. Am J Hematol. 2010;85:810–812.
   PubMed Web of Science ®Google Scholar
• Lindegaard HM, Johansen P, Gröndal G, et al. Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious. Scand J Rheumatol. 2016;45:262–266.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernandez JL, et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum. 2015;44:717–723.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Castañeda S, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol. 2014;32:S79–S89.
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:501–508.
   PubMed Web of Science ®Google Scholar
• Malhotra B, Evans T, Weiss J, et al. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience. Clin Lung Cancer. 2010;11:192–197.
   PubMed Web of Science ®Google Scholar
• Mallett A, Hughes P, Szer J, et al. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J. 2015;45:1054–1065.
   PubMed Web of Science ®Google Scholar
• McIver Z, Stephens N, Grim A, et al. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. Biol Blood Marrow Transplant. 2010;16:1549–1556.
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Tsuji A, Tanioka H, et al. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). Int J Clin Oncol. 2016;21:705–712.
   PubMed Web of Science ®Google Scholar
• Moiseev SV, Novikov PI, Semenkova EN, et al. [Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases]. Ter Arkh. 2013;85:37–43. Russian.
   PubMed Web of Science ®Google Scholar
• Monk JP, Phillips G, Waite R, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006;24:1852–1859.
   PubMed Web of Science ®Google Scholar
• Munemoto Y, Kanda M, Ishibashi K, et al. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer. 2015;15:786.
   PubMed Web of Science ®Google Scholar
• Nagamine R, Chen W, Hara T, et al. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases. Mod Rheumatol. 2009;19:348–350.
   PubMed Web of Science ®Google Scholar
• Narváez J, Díaz-Torné C, Magallares B, et al. Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. PLoS One. 2015;10:e0123392.
   PubMed Web of Science ®Google Scholar
• Néel A, Henry B, Barbarot S, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev. 2014;13:1035–1041.
   PubMed Web of Science ®Google Scholar
• Ogata Y, Shimokawa M, Tanaka T, et al. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). Int J Clin Oncol. 2016;21:335–343.
   PubMed Web of Science ®Google Scholar
• O’Neil BH, Cainap C, Van Cutsem E, et al. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. Clin Colorectal Cancer. 2014;13:156–163.e2.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94:e1554.
   PubMed Web of Science ®Google Scholar
• Ou W, Li N, Wang S-Y, et al. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001). Cancer. 2016;122:740–747.
   PubMed Web of Science ®Google Scholar
• Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25.
   PubMed Web of Science ®Google Scholar
• Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009;27:3284–3289.
   PubMed Web of Science ®Google Scholar
• Pendergraft WF 3rd, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol. 2014;9:736–744.
   PubMed Web of Science ®Google Scholar
• Perry ME, Stirling A, Hunter JA. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clin Rheumatol. 2008;27:923–925.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756–763.
   PubMed Web of Science ®Google Scholar
• Rios-Fernández R, Gutierrez-Salmerón MT, Callejas-Rubio J-L, et al. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol. 2007;157:1271–1273.
   PubMed Web of Science ®Google Scholar
• Rozman S, Sonc M, Novakovic BJ. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. Leuk Lymphoma. 2012;53:1945–1948.
   PubMed Web of Science ®Google Scholar
• Salmon JH, Cacoub P, Combe B, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1:e000034.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94:e400–e406.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Hainsworth JD, Shipley DL, et al. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012;7:196–202.
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Papadaki T, Pontikoglou C, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia. 2008;22:1446–1449.
   PubMed Web of Science ®Google Scholar
• Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209–2214.
   PubMed Web of Science ®Google Scholar
• Tesfa D, Gelius T, Sander B, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol. 2008;25:374–379.
   PubMed Web of Science ®Google Scholar
• Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum. 2015;45:81–85.
   PubMed Web of Science ®Google Scholar
• Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64:1720–1729.
   PubMed Web of Science ®Google Scholar
• Vlahovic G, Meadows KL, Uronis HE, et al. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol. 2012;70:95–102.
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–384.
   PubMed Web of Science ®Google Scholar
• Wu C, Fernandez SA, Criswell T, et al. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas. 2013;42:813–818.
   PubMed Web of Science ®Google Scholar
• Yamasaki M, Murakami I, Nakano K, et al. Carboplatin plus weekly paclitaxel combined with bevacizumab as first-line treatment for non-small cell lung cancer. Anticancer Res. 2017;37:923–928.
   PubMed Web of Science ®Google Scholar
• Yoshinami T, Yagi T, Okuno J, et al. Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer. Breast Cancer. 2017;24:147–151.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–1294.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug the. Arthritis Rheum. 2008;58:2968–2980.
   PubMed Web of Science ®Google Scholar
• Rajakulendran S, Deighton C. Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNFalpha drug. Curr Drug Saf. 2006;1:259–264.
   PubMedGoogle Scholar
• Abou-Jaoude MM, Ghantous I, Almawi WY. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. Mol Immunol. 2003;39:1083–1088.
   PubMed Web of Science ®Google Scholar
• Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol. 2010;29:399–403.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol (Hoboken NJ). 2017;69:668–675.
   PubMed Web of Science ®Google Scholar
• Chang GJ, Mahanty HD, Vincenti F, et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant. 2000;14:550–554.
   PubMed Web of Science ®Google Scholar
• Chen M, Holland MJ, Mir MR, et al. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors. J Drugs Dermatol. 2011;10:280–284.
   PubMed Web of Science ®Google Scholar
• Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118:6299–6305.
   PubMed Web of Science ®Google Scholar
• Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41–48.
   PubMed Web of Science ®Google Scholar
• den Broeder AA, de Jong E, Franssen MJAM, et al. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis. 2006;65:760–762.
   PubMed Web of Science ®Google Scholar
• Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica. 2007;92:1029–1036.
   PubMed Web of Science ®Google Scholar
• Giezen TJ, Mantel-Teeuwisse AK, Ten Berg MJ, et al. Rituximab-induced thrombocytopenia: a cohort study. Eur J Haematol. 2012;89:256–266.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A, Gladieff L, Tholander B, et al. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer. 2013;49:3831–3838.
   PubMed Web of Science ®Google Scholar
• Hong DS, Garrido-Laguna I, Ekmekcioglu S, et al. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014;120:2164–2173.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernandez JL, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol. 2016;34:S44–S53.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Malik L, Beeram M, et al. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2014;74:77–84.
   PubMed Web of Science ®Google Scholar
• Odia Y, Shih JH, Kreisl TN, et al. Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. J Neurooncol. 2014;120:431–440.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32:S75–S79.
   PubMed Web of Science ®Google Scholar
• Pontikaki I, Gerloni V, Gattinara M, et al. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis]. Reumatismo. 2006;58:31–38. Italian.
   PubMedGoogle Scholar
• Reda G, Maura F, Gritti G, et al. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. Am J Hematol. 2012;87:936–937.
   PubMed Web of Science ®Google Scholar
• Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17:1590–1598.
   PubMed Web of Science ®Google Scholar
• Smith CH, Jackson K, Bashir SJ, et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol. 2006;155:160–169.
   PubMed Web of Science ®Google Scholar
• Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant. 2005;35:1003–1010.
   PubMed Web of Science ®Google Scholar
• Zheng JJ, Zhi P, Wang YM, et al. Short-term study of infliximab treatment for Crohn’s disease in China. J Dig Dis. 2011;12:105–109.
   PubMed Web of Science ®Google Scholar
• Zheng -J-J, Wang Y-M, Zhu F, et al. [A study of efficacy of infliximab treatment for Crohn’s disease]. Zhonghua Nei Ke Za Zhi. 2009;48:922–925.
   PubMedGoogle Scholar
• Vermeire S, Noman M, van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology. 2003;125:32–39.
   PubMed Web of Science ®Google Scholar
• Midaglia L, Rodriguez Ruiz M, Munoz-Garcia D. Severe haematological complications during treatment with natalizumab. Mult Scler. 2012;18:1644–1646.
   PubMed Web of Science ®Google Scholar
• Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13:39.
   PubMed Web of Science ®Google Scholar
• Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford). 2012;51:653–662.
   PubMed Web of Science ®Google Scholar
• Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607–1616.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898–906.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–194.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390–1400.
   PubMed Web of Science ®Google Scholar
• Furie R, Toder K, Zapantis E. Lessons learned from the clinical trials of novel biologics and small molecules in lupus nephritis. Semin Nephrol. 2015;35:509–520.
   PubMed Web of Science ®Google Scholar
• Hadjinicolaou AV, Nisar MK, Bhagat S, et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases–a systematic literature review. Rheumatology (Oxford). 2011;50:2297–2305.
   PubMed Web of Science ®Google Scholar
• Kato T, Masuda N, Nakanishi Y, et al. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. Lung Cancer. 2017;104:111–118.
   PubMed Web of Science ®Google Scholar
• Nakashita T, Ando K, Kaneko N, et al. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4:e005615.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68:1580–1584.
   PubMed Web of Science ®Google Scholar
• Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 2005;5:683–690.
   PubMed Web of Science ®Google Scholar
• Salmasi G, Li M, Sivabalasundaram V, et al. Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma. 2015;56:1659–1664.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (London England). 2008;371:987–997.
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470–475.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22:6051–6060.
   PubMed Web of Science ®Google Scholar
• Johnson BE, Kabbinavar F, Fehrenbacher L, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:3926–3934.
   PubMed Web of Science ®Google Scholar
• Huang Y-C, Liu C-J, Liu C-Y, et al. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol. 2011;90:1145–1151.
   PubMed Web of Science ®Google Scholar
• Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172:195–204.
   PubMed Web of Science ®Google Scholar
• Brilli L, Danielli R, Ciuoli C, et al. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine. 2017. DOI:10.1007/s12020-017-1289-2
   PubMedGoogle Scholar
• Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078–4085.
   PubMed Web of Science ®Google Scholar
• Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371–381.
   PubMed Web of Science ®Google Scholar
• Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825–830.
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053.
   PubMed Web of Science ®Google Scholar
• Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593–598.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009;27:1075–1081.
   PubMed Web of Science ®Google Scholar
• Chen C-H, Chen H-A, Wang H-P, et al. Pulmonary arterial hypertension in autoimmune diseases: an analysis of 19 cases from a medical center in northern Taiwan. J Microbiol Immunol Infect. 2006;39:162–168.
   PubMedGoogle Scholar
• Di Giacomo AM, Danielli R, Calabro L, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother. 2011;60:467–477.
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681–6688.
   PubMed Web of Science ®Google Scholar
• Fong L, Kwek SS, O’Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009;69:609–615.
   PubMed Web of Science ®Google Scholar
• Hersh EM, O’Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2011;29:489–498.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010;16:1042–1048.
   PubMed Web of Science ®Google Scholar
• Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:1767–1775.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046–2054.
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005–1016.
   PubMed Web of Science ®Google Scholar
• Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29:455–463.
   PubMed Web of Science ®Google Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–465.
   PubMed Web of Science ®Google Scholar
• Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015;21:749–755.
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372–8377.
   PubMed Web of Science ®Google Scholar
• Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16:1662–1672.
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:75–83.
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–8977.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Who dies from sarcoidosis and why? Am J Respir Crit Care Med. 2011;183:1446–1447.
   Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828–833.
   PubMed Web of Science ®Google Scholar
• Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810–1815.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–212.
   PubMed Web of Science ®Google Scholar
• van den Eertwegh AJM, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509–517.
   PubMed Web of Science ®Google Scholar
• Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950–5956.
   PubMed Web of Science ®Google Scholar
• Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-induced thyroiditis. Comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017. DOI:10.1210/jc.2017-00448
   PubMed Web of Science ®Google Scholar
• Coates LC, McGonagle DG, Bennett AN, et al. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis. 2008;67:729–730.
   Google Scholar
• Foeldvari I, Becker I, Horneff G. Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2015;67:1529–1535.
   PubMed Web of Science ®Google Scholar
• Saurenmann RK, Levin AV, Feldman BM, et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr. 2006;149:833–836.
   PubMed Web of Science ®Google Scholar
• Scrivo R, Spadaro A, Spinelli FR, et al. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum. 2008;58:1555–1556; author reply 1556–1557.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904–1911.
   PubMed Web of Science ®Google Scholar
• Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473–486.
   PubMed Web of Science ®Google Scholar
• Bayry J, Siberil S, Triebel F, et al. Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today. 2007;12:548–552.
   PubMed Web of Science ®Google Scholar
• Wendling D, Vidon C, Godfrin-Valnet M, et al. Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine. 2013;80:670–671.
   Web of Science ®Google Scholar
• Brito-Zeron P, Perez-Alvarez R, Ramos-Casals M. Etanercept and uveitis: friends or foes? Curr Med Res Opin. 2015;31:251–252.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Soto MJ, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22:847–861.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Cuadrado M-J, et al. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep. 2008;10:442–448.
   PubMedGoogle Scholar
• Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.
   PubMed Web of Science ®Google Scholar